Gramics Bio
Gramics Bio is engineering a new class of programmable gene therapy that combines the durability of viral vectors with the safety and manufacturability of non-viral delivery vehicles like lipid nanoparticles. The company builds cell-type-specific intelligence directly into synthetic DNA cargo, enabling durable, re-dosable therapeutics that work with existing LNP delivery systems. Their platform integrates synthetic biology, AI/ML, high-throughput screening, and automation to design and optimize therapeutic sequences for diseases affecting the lung, liver, retina, kidney, and neurons.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
- Artificial Intelligence
- Software Only
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Current gene therapy approaches face a trade-off between viral vectors, which offer durable expression but raise safety and manufacturing concerns, and lipid nanoparticles (LNPs), which are safer and more manufacturable but typically provide only transient effects. Additionally, many existing therapies lack precise cell-type specificity, limiting their efficacy and safety profile for treating genetic diseases.
Solution
Gramics Bio is engineering a new class of programmable gene therapy that combines the durability and dosing frequency of viral vectors with the safety, manufacturability, and scalability of LNPs. Their technology builds intelligence directly into the DNA cargo, programming nuclear entry and therapeutic gene expression on a cell-type and cell-state specific basis. This approach slots into existing LNP delivery vehicles with established safety and biodistribution data, avoiding the need for new chemistries or reformulation. The platform integrates synthetic biology, AI/ML, high-throughput screening, and automation to rationally design, test, and optimize synthetic DNA sequences, enabling durable, re-dosable therapeutics from a single dose.
Target Audience
Primary customers are biopharmaceutical companies and clinical developers focused on monogenic diseases, particularly those pursuing gene therapies for cystic fibrosis, as well as other genetic disorders affecting the lung, liver, retina, kidney, and neurons.
Features
- Programmable synthetic DNA cargo designed for cell-type and cell-state specific nuclear entry and gene expression
- Compatible with existing LNP delivery vehicles, leveraging established safety, biodistribution, and formulation data
- Modular and generalizable platform that can combine with different delivery vehicles and therapeutic modalities
- AI/ML-driven design pipeline integrated with high-throughput screening and automation for rapid sequence optimization
- Low-cost, scalable manufacturing enabled by LNP-based approach
- Re-dosable therapeutic design, allowing repeat administration if needed